{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:08Z","timestamp":1740144068213,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40262-021-00989-0","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T04:15:48Z","timestamp":1616386548000},"page":"1003-1013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol\/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women"],"prefix":"10.1007","volume":"60","author":[{"given":"Robert A.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Lin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheri E.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8402-3271","authenticated-orcid":false,"given":"Juki","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"989_CR1","volume-title":"Prescribing information for Orlissa (elagolix)","author":"AbbVie Inc.","year":"2018","unstructured":"AbbVie Inc. Prescribing information for Orlissa (elagolix). North Chicago: AbbVie Inc.; 2018."},{"issue":"1","key":"989_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/aog.0000000000002675","volume":"132","author":"E Surrey","year":"2018","unstructured":"Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, et al. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018;132(1):147\u201360. https:\/\/doi.org\/10.1097\/aog.0000000000002675.","journal-title":"Obstet Gynecol."},{"issue":"6","key":"989_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40271-019-00394-7","volume":"12","author":"ES Surrey","year":"2019","unstructured":"Surrey ES, Soliman AM, Palac HL, Agarwal SK. Impact of elagolix on workplace and household productivity among women with moderate to severe pain associated with endometriosis: a pooled analysis of two phase III trials. Patient. 2019;12(6):651\u201360. https:\/\/doi.org\/10.1007\/s40271-019-00394-7.","journal-title":"Patient."},{"issue":"3","key":"989_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.fertnstert.2019.04.031","volume":"112","author":"RM Pokrzywinski","year":"2019","unstructured":"Pokrzywinski RM, Soliman AM, Chen J, Snabes M, Diamond MP, Surrey E, et al. Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials. Fertil Steril. 2019;112(3):545\u201351. https:\/\/doi.org\/10.1016\/j.fertnstert.2019.04.031.","journal-title":"Fertil Steril."},{"issue":"5","key":"989_CR5","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1210\/jc.2016-3845","volume":"102","author":"J Ng","year":"2017","unstructured":"Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683\u201391. https:\/\/doi.org\/10.1210\/jc.2016-3845.","journal-title":"J Clin Endocrinol Metab."},{"issue":"59","key":"989_CR6","doi-asserted-by":"publisher","first-page":"99219","DOI":"10.18632\/oncotarget.22381","volume":"8","author":"EC Dun","year":"2017","unstructured":"Dun EC, Taylor HS. Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain. Oncotarget. 2017;8(59):99219\u201320. https:\/\/doi.org\/10.18632\/oncotarget.22381.","journal-title":"Oncotarget."},{"issue":"3","key":"989_CR7","doi-asserted-by":"publisher","first-page":"dgz086","DOI":"10.1210\/clinem\/dgz086","volume":"105","author":"DF Archer","year":"2020","unstructured":"Archer DF, Ng J, Chwalisz K, Chiu YL, Feinberg EC, Miller CE, et al. Elagolix suppresses ovulation in a dose-dependent manner: results from a 3-month, randomized study in ovulatory women. J Clin Endocrinol Metab. 2020;105(3):dgz086. https:\/\/doi.org\/10.1210\/clinem\/dgz086.","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"989_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40262-019-00840-7","volume":"59","author":"M Shebley","year":"2020","unstructured":"Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein CE, et al. Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis. Clin Pharmacokinet. 2020;59(3):297\u2013309. https:\/\/doi.org\/10.1007\/s40262-019-00840-7.","journal-title":"Clin Pharmacokinet."},{"issue":"5 Pt 1","key":"989_CR9","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/s0002-9378(99)70120-1","volume":"181","author":"R Rivera","year":"1999","unstructured":"Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999;181(5 Pt 1):1263\u20139. https:\/\/doi.org\/10.1016\/s0002-9378(99)70120-1.","journal-title":"Am J Obstet Gynecol."},{"key":"989_CR10","unstructured":"US Department of Health and Human Services. Guidance for industry: in vitro metabolism- and transporter-mediated drug-drug interaction studies. 2017. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM581965.pdf. 2017."},{"issue":"5","key":"989_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/0039-128x(77)90018-6","volume":"29","author":"C Gupta","year":"1977","unstructured":"Gupta C, Osterman J, Miljkovic M, Bardin CW. The in vivo metabolism of progestins. IV. The metabolic clearance rate and plasma binding of 6alpha-methylpregn-4-ene-3, 20-dione in women. Steroids. 1977;29(5):669\u201377. https:\/\/doi.org\/10.1016\/0039-128x(77)90018-6.","journal-title":"Steroids"},{"issue":"1","key":"989_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.beem.2012.09.004","volume":"27","author":"R Sitruk-Ware","year":"2013","unstructured":"Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27(1):13\u201324. https:\/\/doi.org\/10.1016\/j.beem.2012.09.004.","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"3","key":"989_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/cts.12499","volume":"11","author":"N Zhang","year":"2018","unstructured":"Zhang N, Shon J, Kim MJ, Yu C, Zhang L, Huang SM, et al. Role of CYP3A in oral contraceptives clearance. Clin Transl Sci. 2018;11(3):251\u201360. https:\/\/doi.org\/10.1111\/cts.12499.","journal-title":"Clin Transl Sci."},{"issue":"2","key":"989_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0010-7824(02)00473-0","volume":"67","author":"GL Hammond","year":"2003","unstructured":"Hammond GL, Abrams LS, Creasy GW, Natarajan J, Allen JG, Siiteri PK. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception. 2003;67(2):93\u20139. https:\/\/doi.org\/10.1016\/s0010-7824(02)00473-0.","journal-title":"Contraception."},{"issue":"6","key":"989_CR15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1124\/dmd.116.073940","volume":"45","author":"D Ahire","year":"2017","unstructured":"Ahire D, Sinha S, Brock B, Iyer R, Mandlekar S, Subramanian M. Metabolite identification, reaction phenotyping, and retrospective drug-drug interaction predictions of 17-deacetylnorgestimate, the active component of the oral contraceptive norgestimate. Drug Metab Dispos. 2017;45(6):676\u201385. https:\/\/doi.org\/10.1124\/dmd.116.073940.","journal-title":"Drug Metab Dispos."},{"issue":"4","key":"989_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s0960-0760(00)00125-4","volume":"74","author":"WG Schoonen","year":"2000","unstructured":"Schoonen WG, Deckers GH, de Gooijer ME, de Ries R, Kloosterboer HJ. Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000;74(4):213\u201322. https:\/\/doi.org\/10.1016\/s0960-0760(00)00125-4.","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"1","key":"989_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0010-7824(90)90093-b","volume":"42","author":"FZ Stanczyk","year":"1990","unstructured":"Stanczyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception. 1990;42(1):67\u201396. https:\/\/doi.org\/10.1016\/0010-7824(90)90093-b.","journal-title":"Contraception."},{"issue":"1\u20132","key":"989_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jsbmb.2007.09.025","volume":"110","author":"T Korhonen","year":"2008","unstructured":"Korhonen T, Turpeinen M, Tolonen A, Laine K, Pelkonen O. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008;110(1\u20132):56\u201366. https:\/\/doi.org\/10.1016\/j.jsbmb.2007.09.025.","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"11","key":"989_CR19","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1124\/dmd.104.000182","volume":"32","author":"B Wang","year":"2004","unstructured":"Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004;32(11):1209\u201312. https:\/\/doi.org\/10.1124\/dmd.104.000182.","journal-title":"Drug Metab Dispos."},{"issue":"5","key":"989_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1055\/s-0028-1095729","volume":"6","author":"WH Bolt","year":"1974","unstructured":"Bolt WH, Kappus H, Bolt HM. Ring A oxidation of 17alpha-ethynylestradiol in man. Horm Metab Res. 1974;6(5):432. https:\/\/doi.org\/10.1055\/s-0028-1095729.","journal-title":"Horm Metab Res."},{"issue":"5","key":"989_CR21","first-page":"500","volume":"33","author":"FP Guengerich","year":"1988","unstructured":"Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol. 1988;33(5):500\u20138.","journal-title":"Mol Pharmacol."},{"issue":"11","key":"989_CR22","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1124\/dmd.32.11","volume":"32","author":"ML Schrag","year":"2004","unstructured":"Schrag ML, Cui D, Rushmore TH, Shou M, Ma B, Rodrigues AD. Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol. Drug Metab Dispos. 2004;32(11):1299\u2013303. https:\/\/doi.org\/10.1124\/dmd.32.11.","journal-title":"Drug Metab Dispos."},{"issue":"3","key":"989_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/jb\/mvi047","volume":"137","author":"S Yasuda","year":"2005","unstructured":"Yasuda S, Suiko M, Liu MC. Oral contraceptives as substrates and inhibitors for human cytosolic SULTs. J Biochem. 2005;137(3):401\u20136. https:\/\/doi.org\/10.1093\/jb\/mvi047.","journal-title":"J Biochem."},{"key":"989_CR24","unstructured":"Elagolix Multidiscipline Review, US FDA Center for Drug Evaluation and Research. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210450Orig1s000MultiD.pdf. Accessed 17 Jan 2020."},{"key":"989_CR25","first-page":"48","volume":"6","author":"AR Polepally","year":"2017","unstructured":"Polepally AR, Dufek MB, Dharia SP, Kamradt K, Lin J, Peloso PM, et al. Drug-drug interaction with midazolam with elagolix, a novel oral GnRH antagonist: analyses of data from two studies. Clin Pharmacol Drug Dev. 2017;6:48.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"7","key":"989_CR26","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1023\/b:pham.0000033017.52484.81","volume":"21","author":"WY Kim","year":"2004","unstructured":"Kim WY, Benet LZ. P-glycoprotein (P-gp\/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004;21(7):1284\u201393. https:\/\/doi.org\/10.1023\/b:pham.0000033017.52484.81.","journal-title":"Pharm Res."},{"issue":"8","key":"989_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/cpdd.640","volume":"8","author":"J Ng","year":"2019","unstructured":"Ng J, Duan WR, Marbury T, Schmidt JM, Klein CE. Elagolix pharmacokinetic profiles in women with renal or hepatic impairment. Clin Pharmacol Drug Dev. 2019;8(8):1053\u201361. https:\/\/doi.org\/10.1002\/cpdd.640.","journal-title":"Clin Pharmacol Drug Dev."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-00989-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-00989-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-00989-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T03:42:16Z","timestamp":1628048536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-00989-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["989"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-00989-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"16 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AbbVie funded the studies presented in this manuscript, and was responsible for the study design, research, analysis, data collection, interpretation of data, and writing, reviewing, and approving of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Juki Ng, Yi-Lin Chiu, and Cheri E. Klein are employees of AbbVie, Inc., and may own stocks or stock options. Robert A. Feldman is an employee of the Baptist Health Medical Group and was the principal investigator for these studies through Miami Research Associates, LLC, where he received payment for his role in leading the studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All studies were conducted in accordance with Good Clinical Practice guidelines and the ethical principles that have their origin in the Declaration of Helsinki. The protocols and informed consent forms were approved by the Ethics Committee or Institutional Review Board at the site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent for participation in the studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials they sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g. protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. This clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan (SAP) and execution of a data sharing agreement (DSA). Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link:","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design and approval of the final content in the manuscript. JN and CK contributed to material preparation, data collection and analysis. Y-LC conducted the study designs, developed statistical methodology, and oversaw the statistical analyses for both studies. RF was the principal investigator for both studies.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}